ArticleClinical lung cancer2025

Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.

Fangdi Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.